Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 1/20 | 0.38 |
| ▸ | FNTB | P49356 | 1/20 | 0.38 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | AGER | Q15109 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TNKS | O95271 | 4/20 | 0.32 |
| ▸ | PARP1 | P09874 | 4/20 | 0.32 |
| ▸ | TNKS2 | Q9H2K2 | 4/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | PARP6 | Q2NL67 | 1/20 | 0.32 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24103207 | 0.71 | KDM4E (0.31) | FNTAFNTBKDM4EMAPT | |
| SCHEMBL8404416 | 0.67 | SSTR4 (0.38) | KDM4EMAPTHSD17B10NPSR1 | |
| SCHEMBL7169099 | 0.65 | CHRNA7 (0.38) | KDM4EMEN1MAPTALOX15CASP1 | |
| SCHEMBL8404413 | 0.65 | KDM4E (0.39) | KDM4EMEN1MAPTALOX15CASP1 | |
| SCHEMBL25948851 | 0.64 | PTPN1 (0.37) | KDM4EMAPTTNKSPARP1TNKS2 | |
| SCHEMBL25948856 | 0.62 | NOS3 (0.34) | RAPGEF4 | |
| SCHEMBL23589214 | 0.62 | EGFR (0.37) | RAPGEF4MEN1KMT2AHSD17B10 | |
| SCHEMBL8404406 | 0.62 | PTPN1 (0.39) | KDM4EMAPTHSD17B10PARP1 | |
| SCHEMBL8404415 | 0.60 | KDM4E (0.43) | KDM4EMAPTNPSR1 | |
| SCHEMBL10889966 | 0.60 | MYC (0.44) | RAPGEF4KDM4EMEN1MAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242533-A9 | SUBSTITUTED FUSED HETEROAROMATIC BICYCLIC COMPOUNDS AS KINASE INHIBITORS AND THE USE THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242533-A9 | SUBSTITUTED FUSED HETEROAROMATIC BICYCLIC COMPOUNDS AS KINASE INHIBITORS AND THE USE THEREOF | ATR, CHEK1, CHEK2 | FNTA 2938/4885FNTB 2490/4885RAPGEF4 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.